Rockwell Medical (RMTI) 10-K 7 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'ROCKWELL MEDICAL, INC.	'	'
Entity Central Index Key	'0001041024	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$135,645,000
Entity Common Stock, Shares Outstanding	'	40,748,161	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
ASSETS	'	'
Cash and Cash Equivalents	$11,881,451	$4,711,730
Investments Available for Sale	12,034,622	'
Accounts Receivable, net of a reserve of $37,000 in 2013 and $26,000 in 2012	4,578,319	4,431,932
Inventory	2,799,648	2,649,639
Other Current Assets	623,734	1,356,131
Total Current Assets	31,917,774	13,149,432
Property and Equipment, net	1,648,949	1,858,442
Intangible Assets	499,715	666,744
Goodwill	920,745	920,745
Other Non-current Assets	1,374,941	429,723
Total Assets	36,362,124	17,025,086
LIABILITIES AND SHAREHOLDERS' EQUITY	'	'
Note Payable	2,308,145	'
Capitalized Lease Obligations	'	2,280
Accounts Payable	8,686,153	14,833,565
Accrued Liabilities	6,647,828	12,015,978
Customer Deposits	207,545	135,133
Total Current Liabilities	17,849,671	26,986,956
Long Term Debt	17,916,914	'
Shareholders' Equity:	'	'
Common Shares, no par value, 40,110,661 and 21,494,696 shares issued and outstanding	154,457,878	92,866,458
Common Share Purchase Warrants, 983,071 and 2,233,240 warrants issued and outstanding	4,895,811	7,178,929
Accumulated Deficit	-158,790,569	-110,007,257
Accumulated Other Comprehensive Income	32,419	'
Total Shareholders' Equity (Deficit)	595,539	-9,961,870
Total Liabilities And Shareholders' Equity	$36,362,124	$17,025,086

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
CONSOLIDATED BALANCE SHEETS	'	'
Allowance for reserve, accounts receivable (in dollars)	$37,000	$26,000
Common Shares, par value (in dollars per share)	$0	$0
Common Shares, shares issued	40,110,661	21,494,696
Common Shares, shares outstanding	40,110,661	21,494,696
Common Share Purchase Warrants, issued	983,071	2,233,240
Common Share Purchase Warrants, outstanding	983,071	2,233,240

CONSOLIDATED_INCOME_STATEMENTS

CONSOLIDATED INCOME STATEMENTS (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CONSOLIDATED INCOME STATEMENTS	'	'	'	'	'	'	'	'	'	'	'
Sales	$13,964,624	$13,094,381	$12,984,164	$12,336,374	$12,999,846	$12,689,339	$12,124,790	$12,028,417	$52,379,543	$49,842,392	$48,966,231
Cost of Sales	11,904,730	11,461,100	11,299,099	11,055,394	11,297,621	11,043,412	10,405,991	10,401,941	45,720,323	43,148,965	43,323,321
Gross Profit	2,059,894	1,633,281	1,685,065	1,280,980	1,702,225	1,645,927	1,718,799	1,626,476	6,659,220	6,693,427	5,642,910
Selling, General and Administrative	3,795,325	3,386,367	3,237,974	3,916,783	3,635,386	3,325,411	2,824,379	2,898,684	14,336,449	12,683,860	9,522,305
Research and Product Development	5,793,579	10,611,219	10,222,721	12,754,518	11,751,256	16,238,450	10,876,396	9,405,547	39,382,037	48,271,649	17,805,362
Operating Income (Loss)	-7,529,010	-12,364,305	-11,775,630	-15,390,321	-13,684,417	-17,917,934	-11,981,976	-10,677,755	-47,059,266	-54,262,082	-21,684,757
Interest and Investment Income	69,317	13,546	4,566	10,672	11,034	42,296	77,091	111,097	98,101	241,518	244,049
Interest (Expense)	-872,412	-857,505	-92,155	-75	-105	-137	-456	-253	-1,822,147	-951	-1,844
Income (Loss) Before Income Taxes	-8,332,105	-13,208,264	-11,863,219	-15,379,724	-13,673,488	-17,875,775	-11,905,341	-10,566,911	-48,783,312	-54,021,515	-21,442,552
Income Tax Expense	'	'	'	'	'	'	'	'	0	'	2,005
Net Income (Loss)	($8,332,105)	($13,208,264)	($11,863,219)	($15,379,724)	($13,673,488)	($17,875,775)	($11,905,341)	($10,566,911)	($48,783,312)	($54,021,515)	($21,444,557)
Basic And Diluted Earnings (Loss) Per Share (in dollars per share)	($0.21)	($0.34)	($0.38)	($0.72)	($0.66)	($0.86)	($0.58)	($0.54)	($1.48)	($2.65)	($1.21)

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)	'	'	'
Net Income (Loss)	($48,783,312)	($54,021,515)	($21,444,557)
Reclassification of Losses Included in Net Loss	'	67,303	84,590
Unrealized Gain (Loss) on Available-for-Sale Investments	32,419	213,809	-152,079
Comprehensive Income (Loss)	($48,750,893)	($53,740,403)	($21,512,046)

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (USD $)	Total	COMMON SHARES	PURCHASE WARRANTS	ACCUMULATED DEFICIT	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Balance at Dec. 31, 2010	$30,537,937	$57,017,236	$8,275,509	($34,541,185)	($213,623)
Balance (purchase warrants in shares) at Dec. 31, 2010	'	'	3,338,569	'	'
Balance (in shares) at Dec. 31, 2010	'	17,513,608	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Net Loss	-21,444,557	'	'	-21,444,557	'
Reclassification of Losses Included in Net Loss	84,590	'	'	'	84,590
Unrealized Gain (Loss) on Available-for-Sale Investments	-152,079	'	'	'	-152,079
Issuance of Common Shares	719,484	719,484	'	'	'
Issuance of Common Shares (in shares)	'	397,054	'	'	'
Issuance of Purchase Warrants	312,325	'	312,325	'	'
Issuance of Purchase Warrants (in shares)	'	'	100,000	'	'
Exercise of Purchase Warrants	3,877,276	5,361,135	-1,483,859	'	'
Exercise of Purchase Warrants (in shares)	-799,340	799,340	-831,129	'	'
Additional Paid In Capital	244,289	244,289	'	'	'
Stock Option Based Expense	3,469,703	3,469,703	'	'	'
Restricted Stock Amortization	596,000	596,000	'	'	'
Balance at Dec. 31, 2011	18,244,968	67,407,847	7,103,975	-55,985,742	-281,112
Balance (purchase warrants in shares) at Dec. 31, 2011	2,607,440	'	2,607,440	'	'
Balance (in shares) at Dec. 31, 2011	18,710,002	18,710,002	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Net Loss	-54,021,515	'	'	-54,021,515	'
Reclassification of Losses Included in Net Loss	67,303	'	'	'	67,303
Unrealized Gain (Loss) on Available-for-Sale Investments	213,809	'	'	'	213,809
Issuance of Common Shares	16,252,695	16,252,695	'	'	'
Issuance of Common Shares (in shares)	1,845,000	2,296,477	'	'	'
Shares Issued in Exchange for Services	1,854,000	1,854,000	'	'	'
Shares Issued in Exchange for Services (in shares)	200,000	200,000	'	'	'
Exercise of Purchase Warrants	1,978,729	2,372,192	-393,463	'	'
Exercise of Purchase Warrants (in shares)	-288,217	288,217	-374,200	'	'
Purchase Warrants Expense	468,417	'	468,417	'	'
Stock Option Based Expense	3,903,795	3,903,795	'	'	'
Restricted Stock Amortization	1,075,929	1,075,929	'	'	'
Balance at Dec. 31, 2012	-9,961,870	92,866,458	7,178,929	-110,007,257	'
Balance (purchase warrants in shares) at Dec. 31, 2012	2,233,240	'	2,233,240	'	'
Balance (in shares) at Dec. 31, 2012	21,494,696	21,494,696	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Net Loss	-48,783,312	'	'	-48,783,312	'
Unrealized Gain (Loss) on Available-for-Sale Investments	32,419	'	'	'	32,419
Issuance of Common Shares	50,431,250	50,431,250	'	'	'
Issuance of Common Shares (in shares)	17,496,721	18,285,132	'	'	'
Shares Issued in Exchange for Services	780,678	780,678	'	'	'
Shares Issued in Exchange for Services (in shares)	200,000	200,000	'	'	'
Exercise of Purchase Warrants	1,164,982	1,593,003	-428,021	'	'
Exercise of Purchase Warrants (in shares)	-130,833	130,833	-130,833	'	'
Expiration of Purchase Warrants	'	2,937,293	-2,937,293	'	'
Expiration of Purchase Warrants (in shares)	'	'	-1,119,336	'	'
Purchase Warrants Expense	1,082,196	'	1,082,196	'	'
Stock Option Based Expense	3,887,695	3,887,695	'	'	'
Restricted Stock Amortization	1,961,501	1,961,501	'	'	'
Balance at Dec. 31, 2013	$595,539	$154,457,878	$4,895,811	($158,790,569)	$32,419
Balance (purchase warrants in shares) at Dec. 31, 2013	983,071	'	983,071	'	'
Balance (in shares) at Dec. 31, 2013	40,110,661	40,110,661	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash Flows From Operating Activities:	'	'	'
Net (Loss)	($48,783,312)	($54,021,515)	($21,444,557)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:	'	'	'
Depreciation and Amortization	1,007,411	1,087,397	1,176,007
Share Based Compensation - Non-employee	1,862,874	2,322,417	312,325
Share Based Compensation- Employees	5,849,196	4,979,724	4,065,703
Loss (Gain) on Disposal of Assets	16,410	17,876	29,093
Loss on Sale of Investments Available for Sale	'	67,303	84,590
Amortization of Debt Issuance Costs	227,059	'	'
Non-Cash Interest Expense	225,059	'	'
Changes in Assets and Liabilities:	'	'	'
(Increase) Decrease in Accounts Receivable	-146,387	-209,116	284,480
(Increase) Decrease in Inventory	-150,009	-145,512	432,751
(Increase) Decrease in Other Assets	669,896	1,855,787	-2,457,370
Increase (Decrease) in Accounts Payable	-6,147,412	9,469,028	1,705,030
Increase (Decrease) in Other Liabilities	-5,295,738	3,829,767	5,028,846
Changes in Assets and Liabilities	-11,069,650	14,799,954	4,993,737
Cash (Used In) Operating Activities	-50,664,953	-30,746,844	-10,783,102
Cash Flows From Investing Activities:	'	'	'
Purchase of Investments Available for Sale	-12,002,203	-2,012,671	-2,000,000
Sale of Investments Available for Sale	'	14,037,255	1,975,244
Purchase of Equipment	-654,197	-507,788	-421,043
Proceeds on Sale of Assets	6,898	1,578	2,985
Purchase of Intangible Assets	'	'	-145,121
Cash Provided By (Used In) Investing Activities	-12,649,502	11,518,374	-587,935
Cash Flows From Financing Activities:	'	'	'
Proceeds from Issuance of Common Shares and Purchase Warrants	51,596,232	18,231,424	4,841,049
Proceeds from the Issuance of Notes Payable	20,000,000	'	'
Debt Issuance Costs	-1,109,776	'	'
Payments on Notes Payable and Capital Lease Obligations	-2,280	-6,470	-18,215
Cash Provided By Financing Activities	70,484,176	18,224,954	4,822,834
Increase (Decrease) In Cash	7,169,721	-1,003,516	-6,548,203
Cash At Beginning Of Period	4,711,730	5,715,246	12,263,449
Cash At End Of Period	11,881,451	4,711,730	5,715,246
Supplemental Cash Flow disclosure	'	'	'
Interest Paid	1,154,752	951	1,844
Non-Cash Investing and Financing Activity - Acquisition of Intangible Assets	'	'	$550,000

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2013
DESCRIPTION OF BUSINESS	'
DESCRIPTION OF BUSINESS	'
	1. DESCRIPTION OF BUSINESS
	We are a fully-integrated pharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. We are also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.
	We are currently developing unique, proprietary renal drug therapies. These novel renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience and outcome. We have obtained global licenses for certain dialysis related drugs which we are developing and seeking FDA approval to market.
	We manufacture, sell and distribute hemodialysis concentrates and other ancillary medical products and supplies used in the treatment of patients with End Stage Renal Disease, or "ESRD". We supply our products to medical service providers who treat patients with kidney disease. Our products are used to cleanse patients' blood and replace nutrients lost during the kidney dialysis process. We primarily sell our products in the United States.
	We are regulated by the Federal Food and Drug Administration ("FDA") under the Federal Drug and Cosmetics Act, as well as by other federal, state and local agencies. We have received 510(k) approval from the FDA to market hemodialysis solutions and powders. We also have 510(k) approval to sell our Dri-Sate Dry Acid Concentrate product line and our Dri-Sate Mixer.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	Our consolidated financial statements include our accounts and the accounts for our wholly owned subsidiary, Rockwell Transportation, Inc.
	All intercompany balances and transactions have been eliminated in consolidation.
	Revenue Recognition
	We recognize revenue at the time we transfer title to our products to our customers consistent with generally accepted accounting principles. Generally, we recognize revenue when our products are delivered to our customer's location consistent with our terms of sale. For international shipments, title generally transfers when the product is shipped.
	We require certain customers, mostly international customers, to pay for product prior to the transfer of title to the customer. Deposits received from customers and payments in advance for orders are recorded as liabilities under Customer Deposits until such time as orders are filled and title transfers to the customer consistent with our terms of sale. At December 31, 2013 and 2012 we had customer deposits of $207,545 and $135,133, respectively.
	Shipping and Handling Revenue and Costs
	Our products are generally priced on a delivered basis with the price of delivery included in the overall price of our products which is reported as sales. Separately identified freight and handling charges are also included in sales.
	We include shipping and handling costs, including expenses of Rockwell Transportation, Inc., in cost of sales.
	Cash and Cash Equivalents
	We consider cash on hand, money market funds and unrestricted certificates of deposit with an original maturity of 90 days or less as cash and cash equivalents.
	Investments Available for Sale
	Investments Available for Sale are short-term investments, consisting principally of investments in short term duration bond funds, and are stated at fair value based upon observed market prices (Level 1 in the fair value hierarchy). Unrealized holding gains or losses on these securities are included in accumulated other comprehensive income (loss). Realized gains and losses, including declines in value judged to be other-than-temporary on available-for-sale securities are included as a component of other income or expense.
	Accounts Receivable
	Accounts receivable are stated at invoice amounts. The carrying amount of trade accounts receivable is reduced by an allowance for doubtful accounts that reflects our best estimate of accounts that may not be collected. We review outstanding trade accounts receivable balances and based on our assessment of expected collections, we estimate the portion, if any, of the balance that may not be collected as well as a general valuation allowance for other accounts receivable based primarily on historical experience. All accounts or portions thereof deemed to be uncollectible are written off to the allowance for doubtful accounts.
	Inventory
	Inventory is stated at the lower of cost or net realizable value. Cost is determined on the first-in first-out (FIFO) method.
	Property and Equipment
	Property and equipment are recorded at cost. Expenditures for normal maintenance and repairs are charged to expense as incurred. Property and equipment are depreciated using the straight-line method over their useful lives, which range from three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of their useful lives or the related lease term.
	Licensing Fees
	License fees related to the technology, intellectual property and marketing rights for dialysate iron covered under certain issued patents have been capitalized and are being amortized over the life of the related patents which is generally 17 years.
	Goodwill, Intangible Assets and Long Lived Assets
	The recorded amounts of goodwill and other intangibles from prior business combinations are based on management's best estimates of the fair values of assets acquired and liabilities assumed at the date of acquisition. Goodwill is not amortized; however, it must be tested for impairment at least annually. Amortization continues to be recorded for other intangible assets with definite lives over their estimated useful lives. Intangible assets subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable.
	An impairment review of goodwill, intangible assets, and property and equipment is performed annually or whenever a change in condition occurs which indicates that the carrying amounts of assets may not be recoverable. Such changes may include changes in our business strategies and plans, changes to our customer contracts, changes to our product lines and changes in our operating practices. We use a variety of factors to assess the realizable value of long-lived assets depending on their nature and use.
	The useful lives of other intangible assets are based on management's best estimates of the period over which the assets are expected to contribute directly or indirectly to our future cash flows. Management annually evaluates the remaining useful lives of intangible assets with finite useful lives to determine whether events and circumstances warrant a revision to the remaining amortization periods. It is reasonably possible that management's estimates of the carrying amount of goodwill and the remaining useful lives of other intangible assets may change in the near term.
	Debt Issuance Costs
	Debt issuance costs are capitalized and amortized over the term of the underlying debt instruments using the effective-interest rate method. Debt issuance costs are recorded as other assets.
	Income Taxes
	We account for income taxes in accordance with the provisions of ASC 740-10, Income Taxes. A current tax liability or asset is recognized for the estimated taxes payable or refundable on tax returns for the year. Deferred tax liabilities or assets are recognized for the estimated future tax effects of temporary differences between book and tax accounting and operating loss and tax credit carryforwards. A valuation allowance is established for deferred tax assets if we determine it to be more likely than not that the deferred tax asset will not be realized. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as income tax expense.
	The effects of tax positions are generally recognized in the financial statements consistent with amounts reflected in returns filed, or expected to be filed, with taxing authorities. For tax positions that the Company considers to be uncertain, current and deferred tax liabilities are recognized, or assets derecognized, when it is probable that an income tax liability has been incurred and the amount of the liability is reasonably estimable, or when it is probable that a tax benefit, such as a tax credit or loss carryforward, will be disallowed by a taxing authority. The amount of unrecognized tax benefits related to tax positions is insignificant.
	Research and Product Development
	We recognize research and product development costs as expenses as incurred. We incurred product development and research costs related to the commercial development, patent approval and regulatory approval of new products, including Triferic®, aggregating approximately $39,382,000, $48,272,000, and $17,805,000 in 2013, 2012 and 2011, respectively.
	Share Based Compensation
	We measure the cost of employee services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards in accordance with ASC 718-10, Compensation—Stock Compensation. The cost of equity based compensation is recognized as compensation expense over the vesting period of the awards.
	We estimate the fair value of compensation involving stock options utilizing the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, expected volatility of our stock price over the expected option term, and an expected forfeiture rate, and is subject to various assumptions. We believe the valuation methodology is appropriate for estimating the fair value of stock options we grant to employees and directors which are subject to ASC 718-10 requirements. These amounts are estimates and thus may not be reflective of actual future results or amounts ultimately realized by recipients of these grants.
	Employee Retirement Plans
	We are the sponsor of a non-contributory 401(k) Employee Savings Plan.
	Earnings per Share
	We computed our basic earnings (loss) per share using weighted average shares outstanding for each respective period. Diluted earnings per share also reflect the weighted average impact from the date of issuance of all potentially dilutive securities, consisting of stock options and common share purchase warrants, unless inclusion would have had an anti-dilutive effect. Actual weighted average shares outstanding used in calculating basic and diluted earnings per share were:
		2013			2012		2011
	Basic Weighted Average Shares Outstanding		32,882,333			20,395,889		17,774,865
	Effect of Dilutive Securities		-0-			-0-		-0-
	Diluted Weighted Average Shares Outstanding		32,882,333			20,395,889		17,774,865
	For 2013, 2012 and 2011, the dilutive effect of stock options and common share purchase warrants have not been included in the average shares outstanding for the calculation of diluted loss per share as the effect would be anti-dilutive as a result of our net loss in these periods. The table below summarizes potentially dilutive securities.
		2013		2012		2011
	Stock Options	6,228,000		5,989,200		5,482,135
	Range of Exercise Prices of Stock Options	$2.79 - $11.44		$1.81 - $10.20		$0.55 - $10.20
	Common Share Purchase Warrants	983,071		2,233,240		2,607,440
	Range of Exercise Prices of Warrants	$9.55 - $10.25		$6.14 - $10.25		$6.14 - $10.25
	Unvested Restricted Common Shares	545,000		545,000		310,000
	Investments Available for Sale
	Investments Available for Sale are short-term investments, consisting principally of investments in short term duration bond funds, and are stated at fair value. Unrealized holding gains or losses on these securities are included in accumulated other comprehensive income (loss). Realized gains and losses, including declines in value judged to be other-than-temporary on available-for-sale securities are included as a component of other income or expense.
	Management evaluates securities for other-than-temporary impairment ("OTTI") on a quarterly basis, and more frequently when conditions warrant such an evaluation. When evaluating investment securities, consideration is given to the length of time and the extent to which the fair value has been less than cost, the financial condition and near-term prospects of the issuer, and whether the Company has the intent to sell the security or more likely than not will be required to sell the security before its anticipated recovery. The assessment of whether an OTTI exists involves a high degree of subjectivity and judgment and is based on the information available to management at a point in time.
	Other Comprehensive Income (Loss)
	Accounting principles generally require that recognized revenue, expenses, gains, and losses be included in net income. Certain changes in assets and liabilities, however, such as unrealized gains and losses on available for sale securities, are reported as a direct adjustment to the equity section of the balance sheet. Such items, along with net income (loss), are considered components of comprehensive income (loss). Accumulated Other Comprehensive Income (Loss) consists solely of unrealized gains and losses on available-for-sale investment securities.
	Estimates in Preparation of Financial Statements
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

FAIR_MARKET_VALUE_MEASUREMENTS

FAIR MARKET VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
Fair Market Value Measurements	'
Fair Market Value Measurements	'
	3. FAIR MARKET VALUE MEASUREMENTS
	Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
	Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2:	Observable prices that are based on inputs not quoted in active markets, but corroborated by market data.
	Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considering counterparty credit risk in its assessment of fair value. The following methods, assumptions, and valuation techniques were used to measure different financial assets and liabilities at fair value and in estimating its fair value disclosures for financial instruments.
	Cash and Cash Equivalents:    The carrying amounts reported in the consolidated statements of financial condition for cash and cash equivalents is deemed to approximate fair value
	Investment Securities:    Fair values for investment securities are determined by quoted market prices if available.
	Notes Payable:    The fair value of notes payable is based on the discounted value of contractual cash flows using rates currently offered for similar maturities.
	Accounts receivable, Accounts Payable and Accrued Liabilities:    The fair value of trade receivables and payables approximate their carrying amounts due to the short duration before collection or payment.
	Based on the foregoing methods and assumptions, the carrying value and fair value of the Company's financial instruments other than trade receivables and payables are as follows (in thousands):
		Carrying		Fair value		Level 1		Level 2		Level 3
		value
	As of December 31, 2013
	Financial assets
	Cash and cash equivalents	$	11,881	$	11,881	$	11,811	$	—	$	—
	Investment securities available for sale		12,035		12,035		12,035		—		—
	Financial liabilities
	Notes Payable		20,000		20,000		—		20,000		—
	As of December 31, 2012
	Financial assets
	Cash and cash equivalents		4,712		4,712		4,712		—		—
	Investment securities available for sale		—		—		—		—		—
	Financial liabilities
	Notes Payable		—		—		—		—		—
	The Company also has certain non-financial assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. No such measurements were required in 2013 or 2012.

INVESTMENTS_IN_AVAILABLE_FOR_S

INVESTMENTS IN AVAILABLE FOR SALE SECURITIES	12 Months Ended
	Dec. 31, 2013
INVESTMENTS IN AVAILABLE FOR SALE SECURITIES	'
INVESTMENTS IN AVAILABLE FOR SALE SECURITIES	'
	4. INVESTMENTS IN AVAILABLE FOR SALE SECURITIES
	As of December 31, 2013, we held investments in available for sale securities in several short term bond funds. These funds generally held high credit quality short term debt instruments. These debt instruments were subject to changes in fair market value due to changes in interest rates. The market value of these investments was $12,034,622 as of December 31, 2013. In 2013 we purchased securities with a market value of $12,002,203 and had unrealized gains of $44,070 and unrealized losses of $11,652 as of December 31, 2013.
	As of December 31, 2012, we did not hold any investments in available for sale securities. In 2012, we sold securities with a market value of $14,037,255 with an average cost basis of $14,104,558. We realized gains of $10,436 and losses of $77,739 from sales of available-for-sale securities.

SIGNIFICANT_MARKET_SEGMENTS

SIGNIFICANT MARKET SEGMENTS	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT MARKET SEGMENTS	'
SIGNIFICANT MARKET SEGMENTS	'
	5. SIGNIFICANT MARKET SEGMENTS
	We operate in one market segment which involves the manufacture and distribution of hemodialysis concentrates, dialysis kits and ancillary products used in the dialysis process to hemodialysis clinics. For the years ended December 31, 2013, 2012 and 2011, one customer, DaVita Healthcare Partners, Inc., accounted for 49%, 49% and 48% of our sales, respectively. Our accounts receivable from this customer were $1,886,000 and $2,352,000 as of December 31, 2013 and 2012, respectively. This key customer is important to our business and the loss of its business could have a material adverse effect on our business, financial condition and results of operations. No other customer accounted for more than 10% of our sales in any of the last three years.
	The majority of our international sales in each of the last three years were sales to domestic distributors that were resold to end users outside the United States. Our sales to foreign customers and distributors were less than 5% of our total sales in 2013, 2012 and 2011. We have no assets outside the United States. Our total international sales, including sales to domestic distributors for resale outside the United States, aggregated 12%, 11% and 13%, of overall sales in 2013, 2012 and 2011, respectively.

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2013
INVENTORY	'
INVENTORY	'
	6. INVENTORY
	Components of inventory as of December 31, 2013 and 2012 are as follows:
		2013		2012
	Raw Materials	$	1,142,776	$	1,018,648
	Work in Process		254,714		179,922
	Finished Goods		1,402,158		1,451,069
	Total	$	2,799,648	$	2,649,639

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
PROPERTY AND EQUIPMENT	'
PROPERTY AND EQUIPMENT	'
	7. PROPERTY AND EQUIPMENT
	Major classes of property and equipment, stated at cost, as of December 31, 2013 and 2012 are as follows:
		2013			2012
	Leasehold Improvements	$	517,907		$	463,080
	Machinery and Equipment		6,398,366			6,046,055
	Information Technology & Office Equipment		1,961,968			1,911,493
	Laboratory Equipment		513,616			505,883
	Transportation Equipment		374,035			383,711
			9,765,922			9,310,222
	Accumulated Depreciation		(8,116,973	)		(7,451,780	)
	Net Property and Equipment	$	1,648,949		$	1,858,442
	Below is a summary of depreciation expense by period:
		2013			2012			2011
	Depreciation expense	$	840,382		$	920,368		$	1,141,545

GOODWILL_AND_INTANGIBLE_ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
GOODWILL AND INTANGIBLE ASSETS	'
GOODWILL AND INTANGIBLE ASSETS	'
	8. GOODWILL AND INTANGIBLE ASSETS
	Total goodwill was $920,745 at December 31, 2013 and 2012. We completed our annual impairment tests as of November 30, 2013 and 2012, and determined that no adjustment for impairment of goodwill was required.
	We have entered into a global licensing agreement for certain patents covering a therapeutic drug compound to be delivered using our dialysate product lines. We intend to seek FDA approval for this product. We have capitalized the licensing fees paid for the rights to use this patented technology as an intangible asset.
	During 2011, we acquired an abbreviated new drug application ("ANDA") for a generic version of an intravenous vitamin-D analogue, Calcitriol. Total capitalized costs related to this ANDA were approximately $695,000. These costs are being amortized over a five year period.
		2013			2012			2011
	Capitalized Licensing Fees	$	1,070,126		$	1,070,126		$	1,070,126
	Accumulated Amortization		(570,411	)		(403,382	)		(236,353	)
	Capitalized Licensing Fees, Net of Amortization	$	499,715		$	666,744		$	833,773
	Amortization Expense	$	167,029		$	167,029		$	28,005
	Our policy is to amortize licensing fees over the life of the patents pertaining to certain licensing agreements. Estimated amortization expense for licensing fees for 2014 through 2016 is approximately $167,000 per year. Our Triferic® licensing agreement, which is with a company owned by our chief scientific officer, requires additional payments by the Company upon achievement of certain milestones.

OTHER_CURRENT_ASSETS

OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2013
OTHER CURRENT ASSETS	'
OTHER CURRENT ASSETS	'
	9. OTHER CURRENT ASSETS
	The Company has entered into contracts with contract research organizations for the purpose of conducting human clinical research trials and advanced funds to contract research organizations to partially offset future service costs and expenses under these contracts. All such advances had been used to offset costs as of December 31, 2013. As of December 31, 2012, such advances classified as other current assets aggregated $852,555.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2013
NOTES PAYABLE	'
NOTES PAYABLE	'
	10. NOTES PAYABLE
	In 2013, the Company entered into a loan and security agreement (the "Loan Agreement") with Hercules Technology III, L.P. ("Hercules") pursuant to which the Company received a loan in the aggregate principal amount of $20.0 million. The Company is required to repay the aggregate principal balance under the Loan Agreement in 30 equal monthly installments of principal and interest commencing on September 1, 2014. The Company will be required to make monthly interest only payments through August 31, 2014.
	The loan will mature and become due on March 1, 2017, subject to adjustment as provided below, and will bear interest at the greater of (i) 12.50% plus the prime rate as reported in The Wall Street Journal minus 3.25%, or (ii) 12.50%. The loan may be prepaid at any time after June 14, 2014 without penalty and will mature and become due upon any change in control of the Company. The Company paid debt issuance costs of $1.1 million including a fee of $0.2 million at closing to Hercules, which are recorded as a noncurrent asset, and is required to pay a fee of $1.1 million upon any prepayment or at maturity. The $1.1 million fee due upon any prepayment or at maturity is being accrued using the effective interest rate method over the life of the loan. The effective interest rate of the loan is 14.5%.
	In connection with the loan, the Company granted Hercules a security interest in substantially all of the Company's assets other than motor vehicles, real property and certain intellectual property and other interests. The Loan Agreement provides for standard indemnification of Hercules and contains representations, warranties and non-financial covenants that, among other things, limit the Company's ability to incur additional indebtedness, transfer assets, acquire assets of or merge with another entity and pay dividends to the Company's shareholders. The Loan Agreement defines event of default, to include, among other events, the occurrence of an event that results in a material adverse effect upon the Company's business operations, properties, assets or condition (financial or otherwise), the collateral or the perfection of the security interest, or the Company's ability to perform its obligations under the Loan Agreement.
	As of December 31, 2013, the balance of the above debt matures as follows:
	2014	$	2,308,145
	2015		7,544,935
	2016		8,555,035
	2017		1,591,885
	Total Principal Payable	$	20,000,000

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2013
ACCRUED LIABILITIES	'
ACCRUED LIABILITIES	'
	11. ACCRUED LIABILITIES
	We had the following accrued liabilities as of December 31, 2013 and 2012:
		2013		2012
	Accrued Research & Development Expense	$	3,237,093	$	9,832,357
	Accrued Compensation and Benefits		1,490,953		1,118,475
	Other Accrued Liabilities		1,919,782		1,065,146
	Total Accrued Liabilities	$	6,647,828	$	12,015,978

OPERATING_LEASES

OPERATING LEASES	12 Months Ended
	Dec. 31, 2013
OPERATING LEASES	'
OPERATING LEASES	'
	12. OPERATING LEASES
	We lease our production facilities and administrative offices as well as certain equipment used in our operations. The lease terms range from monthly to seven years. We occupy a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2015. We also occupy a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2015. In addition, we lease a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2016.
		2013		2012		2011
	Rent Expense Recognized Under Operating Leases	$	2,163,281	$	1,955,626	$	2,001,094
	Future minimum rental payments under operating lease agreements are as follows:
	Year ending December 31, 2014	$	1,500,697
	Year ending December 31, 2015		1,163,791
	Year ending December 31, 2016		765,542
	Year ending December 31, 2017		740,058
	Year ending December 31, 2018		732,079
	Year ending December 31, 2019 and thereafter		599,559
	Total	$	5,501,726

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
INCOME TAXES	'
INCOME TAXES	'
	13. INCOME TAXES
	A reconciliation of income tax expense at the statutory rate to income tax expense at our effective tax rate is as follows:
		2013			2012			2011
	Tax Expense Computed at 34% of Pretax Income	$	(16,583,000	)	$	(18,367,000	)	$	(7,291,000	)
	State Income Taxes		—			—			2,005
	Effect of Change in Valuation Allowance		(16,583,000	)		(18,367,000	)		(7,291,000	)
	Total Income Tax Expense	$	-0-		$	-0-		$	2,005
	The details of the net deferred tax asset are as follows:
		December 31,
		2013			2012
	Deferred tax assets:
	Net Operating Loss Carryforward	$	49,426,000		$	33,016,000
	Stock Based Compensation		6,839,000			5,398,000
	Accrued Expenses		334,000			274,000
	Inventories		65,000			66,000
	Prepaid Expenses		—			51,000
	Workers' Compensation Reserve		60,000			—
	Accounts Receivable		13,000			9,000
	Total Deferred Tax Assets		56,737,000			38,814,000
	Deferred Tax Liabilities:
	Tax over Book Depreciation		118,000			276,000
	Goodwill & Intangible Assets		225,000			272,000
	Prepaid Expenses		122,000			—
	Total Deferred Tax Liabilities		465,000			548,000
	Subtotal		56,272,000			38,266,000
	Valuation Allowance		(56,272,000	)		(38,266,000	)
	Net Deferred Tax Asset	$	-0-		$	-0-
	Deferred tax assets result primarily from net operating loss carryforwards. For tax purposes, we have net operating loss carryforwards of approximately $145,371,000 that expire between 2018 and 2033.
	In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized upon the generation of future taxable income during the periods in which those temporary differences become deductible. We recognized no income tax expense or benefit for the years ended December 31, 2013, 2012 and 2011. While we anticipate generating income within the next year or two, we expect to incur operating losses until our drug products are approved to be marketed and manufactured. Considered together with our limited history of operating income and our net losses in 2013, 2012 and 2011, management has placed a full valuation allowance against the net deferred tax assets as of December 31, 2013 and 2012. The portion of the valuation allowance resulting from excess tax benefits on share based compensation that would be credited directly to contributed capital if recognized in subsequent periods is $3.7 million.
	The Company accounts for its uncertain tax positions in accordance with ASC 740-10, Income Taxes and the amount of unrecognized tax benefits related to tax positions is not significant at December 31, 2013 and 2012.

CAPITAL_STOCK

CAPITAL STOCK	12 Months Ended
	Dec. 31, 2013
CAPITAL STOCK	'
CAPITAL STOCK	'
	14. CAPITAL STOCK
	Our authorized capital stock consists of 2,000,000 preferred shares, none of which were issued or outstanding at December 31, 2013, 2012 and 2011, and 120,000,000 common shares, no par value per share, of which the following shares were outstanding:
		2013			2012			2011
	Shares outstanding as of December 31,		40,110,661			21,494,696			18,710,002
	Summary of Share Issuances:
	Shares Issuances related to Equity Compensation:
	Shares issued upon exercise of stock options by employees		478,411			216,477			397,054
	Proceeds realized from stock option exercises	$	766,926		$	132,026		$	719,484
	Average exercise price of options exercised	$	1.6		$	0.61		$	1.81
	Restricted Stock Grants		310,000			235,000			—
	Share issuances related to Warrant Exercises
	Shares issued upon the exercise of warrants		130,833			288,217			799,340
	Proceeds realized from warrant exercises	$	1,164,982		$	1,982,720		$	3,877,276
	Share issuances related to Equity Offerings
	Shares issued pursuant to equity offerings		17,496,721			1,845,000
	Proceeds realized from equity offerings	$	49,664,324		$	16,120,669
	Share issuances in Exchange for Services
	Share issuances in Exchange for Services		200,000			200,000
	Value of Shares issued in Exchange for Services	$	780,678		$	1,854,000
	Common Shares
	Holders of the common shares are entitled to one vote per share on all matters submitted to a vote of our shareholders and are entitled to receive dividends when and if declared by the Board of Directors. The Board is authorized to issue additional common shares within the limits of the Company's Articles of Incorporation without further shareholder action, subject to applicable stock exchange rules.
	Warrants
	We had 983,071 common share purchase warrants outstanding at December 31, 2013, all of which were exercisable as of December 31, 2013. During 2013, we agreed to extend the term of 1,008,336 common share purchase warrants until July 31, 2013 and incurred an expense of $927,669 related to the extension of these warrants.
	We had 2,233,240 common share purchase warrants outstanding at December 31, 2012, of which 2,133,240 were exercisable as of December 31, 2012. During 2012, we agreed to extend the term of 1,079,169 common share purchase warrants until January 28, 2013 and incurred an expense of $280,600 related to the extension of these warrants. We also extended the term of 80,000 common share purchase warrants until November 28, 2013 and incurred an expense of $33,600 related to the extension of the term of these warrants.
	We had 2,607,440 common share purchase warrants outstanding at December 31, 2011 of which 2,507,440 were exercisable as of December 31, 2011. During 2011, we issued 100,000 warrants with an exercise price of $10.25 related to a supply agreement with a major customer. Those warrants are exercisable after December 31, 2013 and expire March 31, 2014. Also, during 2011, we agreed to extend the term of 245,000 warrants issued in November 2008 in consideration for services. The term was extended from November 5, 2011 to May 4, 2012. We recognized an expense of $165,850 related to the extension of the term of these warrants.
	Warrants were valued using the Black Scholes model. In 2013, 2012 and 2011 we recognized $1,082,196, $468,417 and $312,000 in expense related to services and consideration provided in exchange for warrants.
	Outstanding warrants by exercise price consisted of the following as of December 31, 2013, 2012 and 2011:
	Exercise Price	Expiration Date		2013			2012			2011
	$9.55	10/5/14			883,071			883,071			883,071
	$10.25	3/31/14			100,000			100,000			100,000
	$7.18	1/28/13			—			1,059,169			1,079,169
	$8.00	5/28/13			—			104,000			105,000
	$10.00	11/28/13			—			80,000			80,000
	$6.14	3/8/13			—			7,000			15,000
	$7.00	5/4/12			—			—			200,000
	$9.55	10/5/12			—			—			85,200
	$6.50	9/30/12			—			—			60,000
	Total				983,071			2,233,240			2,607,440

LONG_TERM_INCENTIVE_PLAN_STOCK

LONG TERM INCENTIVE PLAN & STOCK OPTIONS	12 Months Ended
	Dec. 31, 2013
LONG TERM INCENTIVE PLAN & STOCK OPTIONS	'
LONG TERM INCENTIVE PLAN & STOCK OPTIONS	'
	15. LONG TERM INCENTIVE PLAN & STOCK OPTIONS
	Long Term Incentive Plan & Stock Options
	The Board of Directors adopted the Rockwell Medical, Inc., 2007 Long Term Incentive Plan ("LTIP") on April 11, 2007 as a replacement for the 1997 Stock Option Plan (the "Old Plan") which was terminated as to future grants. No options were granted under the Old Plan after 2006. There are 7,750,000 common shares reserved for issuance under the LTIP. The Compensation Committee of the Board of Directors (the "Committee") is responsible for the administration of the LTIP including the grant of stock based awards and other financial incentives including performance based incentives to employees, non-employee directors and consultants.
	The Committee determines the terms and conditions of options and other equity based incentives including, but not limited to, the number of shares, the exercise price, term of option and vesting requirements. The Committee approved stock option grants during 2013, 2012 and 2011 and restricted stock grants during 2013 and 2012. The stock option awards were granted with an exercise price equal to the market price of the Company's stock on the date of the grant. The options expire 10 years from the date of grant or upon termination of employment and generally vest in three equal annual installments beginning on the first anniversary of the date of grant.
	Restricted Stock Grants
	We granted 310,000 and 235,000 restricted shares in 2013 and 2012, respectively under the LTIP. These restricted stock grants were valued at the market price on the date of grant. The 2013 grant vests on the fourteen month anniversary of the grant with vesting conditioned upon continued employment with the Company. The 2012 grant vests two years after the date of grant with vesting conditioned upon continued employment with the Company.
		2013			2012			2011
	Restricted Shares Granted		310,000			235,000			—
	Market Value Per Share on Grant Date	$	3.94		$	9.45
	Expense related to All Restricted Shares	$	1,961,501		$	1,075,929		$	596,000
	Unearned Stock Based Compensation for All Restricted Stock Awards Attributable to Future Periods.	$	1,147,935
	Stock Option Grants
	Our standard stock option agreement allows for the payment of the exercise price of vested stock options either through cash remittance in exchange for newly issued shares, or through non-cash exchange of previously issued shares held by the recipient for at least six months in exchange for our newly issued shares. The latter method results in no cash being received by us, but also results in a lower number of total shares being outstanding subsequently as a direct result of this exchange of shares. Shares returned to us in this manner would be retired.
	In 2013, 2012 and 2011, the Company received cash proceeds of $766,926, $132,026 and $719,484, respectively, in exchange for shares issued upon the exercise of options during the year. No income tax benefits were recognized during 2013, 2012 and 2011 related to stock option activity as the Company has a full valuation allowance recorded against its deferred tax assets. However, tax benefits for the excess of the value of the shares issued over the price paid of $609,000, $494,000 and $772,000, were created in 2013, 2012, and 2011. The cumulative excess tax benefit at December 31, 2013 is $3.0 million, which when realized, will be credited directly to stockholders' equity.
	A summary of the status of the LTIP and the Old Plan is as follows:
		SHARES			WEIGHTED			AGGREGATE
					AVERAGE			INTRINSIC
					EXERCISE			VALUE
					PRICE
	Outstanding at December 31, 2010		5,289,334			4.52		$	17,879,160
	Granted		839,000			8.54
	Exercised		(416,201	)		1.81		$	2,571,874
	Forfeited		(229,998	)		6.61
	Outstanding at December 31, 2011		5,482,135			5.23		$	17,761,008
	Granted		871,000			9.62
	Exercised		(223,601	)		0.59		$	1,486,470
	Forfeited		(140,334	)		8.66
	Outstanding at December 31, 2012		5,989,200			5.95		$	12,559,074
	Granted		920,500			5.74
	Exercised		(623,700	)		1.23		$	1,920,557
	Forfeited		(58,000	)		8.31
	Outstanding at December 31, 2013		6,228,000			6.27		$	25,956,880
	OPTIONS OUTSTANDING									OPTIONS EXERCISABLE
	RANGE OF EXERCISE PRICES	NUMBER OF			REMAINING		WEIGHTED			NUMBER OF		WEIGHTED
		OPTIONS			CONTRACTUAL		EXERCISE			OPTIONS		AVERAGE
					LIFE		PRICE					EXERCISE
												PRICE
	$2.79 to $4.98		1,894,600		0.2 - 9.6 yrs.		$	3.71			1,759,100	$	3.72
	$5.34 to $7.13		2,799,400		3.8 - 9.7 yrs.		$	6.43			2,010,467	$	6.56
	$8.35 to 11.44		1,534,000		5.8 - 9.8 yrs.		$	9.15			744,000	$	8.94
	Total		6,228,000		5.6 yrs.		$	6.27			4,513,567	$	5.85
	Intrinsic Value	$	25,956,880							$	20,726,770
		NUMBER OF			WEIGHTED
		UNVESTED			AVERAGE
		OPTIONS			FAIR MARKET
					VALUE AT
					GRANT DATE
	As of December 31, 2010		1,609,111
	Granted		839,000		$	5.06
	Forfeited		(229,998	)
	Vested		(688,780	)
	As of December 31, 2011		1,529,333
	Granted		871,000		$	5.93
	Forfeited		(140,334	)
	Vested		(680,999	)
	As of December 31, 2012		1,579,000
	Granted		920,500		$	3.33
	Forfeited		(58,000	)
	Vested		(727,067	)
	As of December 31, 2013		1,714,433
	The Company values stock options awarded using the Black-Scholes method. Assumptions used in the stock option valuations were :
		2013		2012		2011
	Volatility of share price	59 - 67%		64 - 65%		63 - 64%
Risk free interest rate	0.1 - 2.0%		0.8 - 1.2%		1.1 - 2.6%
Expected option life	1 - 6 yrs.		6 yrs.		6 yrs.
Dividend Yield	0.00%		0.00%		0.00%
We believe this valuation methodology is appropriate for estimating the fair value of stock options we grant to employees and directors which are subject to ASC 718-10 requirements. We primarily base our determination of expected volatility through our assessment of the historical volatility of our common shares. We do not believe that we are able to rely on our historical stock option exercise and post-vested termination activity to provide accurate data for estimating our expected term for use in determining the fair value of these options. Therefore, as allowed by Staff Accounting Bulletin (SAB) No. 107, Share-Based Payment, we have opted to use the simplified method for estimating the expected option term equal to the midpoint between the vesting period and the contractual term. The contractual term of the option is 10 years from the date of grant and the vesting term of the option is three years from date of grant. Risk free interest rates utilized are based upon published U.S. Treasury yield curves at the date of the grant for the expected option term. We also granted 25,000 options under a one year vesting term during 2013.
For the years ended December 31, 2013, 2012 and 2011, we recognized compensation expense of $3,877,695, $3,903,795 and $3,469,703, respectively related to options granted to employees under the LTIP with a corresponding credit to common stock. At December 31, 2013, the amount of unrecorded stock-based compensation expense for stock options attributable to future periods was approximately $4,117,156 which is expected to be amortized to expense over the remaining vesting periods of the options of 1 to 33 months.
As of December 31, 2013, the remaining number of common shares available for equity awards under the LTIP was 1,409,165.

RISK_MANAGEMENT

RISK MANAGEMENT	12 Months Ended
	Dec. 31, 2013
RISK MANAGEMENT	'
RISK MANAGEMENT	'
	16. RISK MANAGEMENT
	Insurance
	We evaluate various kinds of risk that we are exposed to in our business. In our evaluation of risk, we evaluate options and alternatives to mitigating such risks. For certain insurable risks we may acquire insurance policies to protect against potential losses or to partially insure against certain risks. For our subsidiary, Rockwell Transportation, Inc., we maintain a partially uninsured workers' compensation plan. Under the policy, the Company's self-insurance retention is $350,000 per occurrence and $784,222 in aggregate coverage for the policy year ending July 1, 2014. The total amount at December 31, 2013 by which retention limits exceed the claims paid and accrued is approximately $779,000 for the policy year ending July 1, 2014. Estimated additional future claims subject to payment by the Company of approximately $293,000 has been accrued for the year ended December 31, 2013.
	At December 31, 2013, approximately $350,000 was held in cash collateral and escrow by the insurance carrier for workers' compensation insurance. At December 31, 2013 amounts held in cash collateral and escrow are included in prepaid expenses and other non-current assets in the consolidated financial statements.

QUARTERLY_RESULTS_OF_OPERATION

QUARTERLY RESULTS OF OPERATIONS	12 Months Ended
	Dec. 31, 2013
QUARTERLY RESULTS OF OPERATIONS	'
QUARTERLY RESULTS OF OPERATIONS	'
	17. QUARTERLY RESULTS OF OPERATIONS
	The following is a summary of the quarterly results of operations for the years ended December 31, 2013 and 2012.
		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	2013
	Sales	$	12,336,374		$	12,984,164		$	13,094,381		$	13,964,624
	Cost of Sales		11,055,394			11,299,099			11,461,100			11,904,730
	Gross Profit		1,280,980			1,685,065			1,633,281			2,059,894
	Selling, General and Administrative		3,916,783			3,237,974			3,386,367			3,795,325
	Research and Product Development		12,754,518			10,222,721			10,611,219			5,793,579
	Operating Income (Loss)		(15,390,321	)		(11,775,630	)		(12,364,305	)		(7,529,010	)
	Interest and Investment Income, net		10,672			4,566			13,546			69,317
	Interest Expense		75			92,155			857,505			872,412
	Income (Loss) Before Income Taxes		(15,379,724	)		(11,863,219	)		(13,208,264	)		(8,332,105	)
	Income Tax Expense		—			—			—			—
	Net Income (Loss)	$	(15,379,724	)	$	(11,863,219	)	$	(13,208,264	)	$	(8,332,105	)
	Basic And Diluted Earnings (Loss) Per Share	$	(.72	)	$	(.38	)	$	(.34	)	$	(.21	)
		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	2012
	Sales	$	12,028,417		$	12,124,790		$	12,689,339		$	12,999,846
	Cost of Sales		10,401,941			10,405,991			11,043,412			11,297,621
	Gross Profit		1,626,476			1,718,799			1,645,927			1,702,225
	Selling, General and Administrative		2,898,684			2,824,379			3,325,411			3,635,386
	Research and Product Development		9,405,547			10,876,396			16,238,450			11,751,256
	Operating Income (Loss)		(10,677,755	)		(11,981,976	)		(17,917,934	)		(13,684,417	)
	Interest and Investment Income, net		111,097			77,091			42,296			11,034
	Interest Expense		253			456			137			105
	Income (Loss) Before Income Taxes		(10,566,911	)		(11,905,341	)		(17,875,775	)		(13,673,488	)
	Income Tax Expense		—			—			—			—
	Net Income (Loss)	$	(10,566,911	)	$	(11,905,341	)	$	(17,875,775	)	$	(13,673,488	)
	Basic And Diluted Earnings (Loss) Per Share	$	(.54	)	$	(.58	)	$	(.86	)	$	(.66	)

SCHEDULE_II_VALUATION_AND_QUAL

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2013
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	'
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	'
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
		Balance at		Additions		(Deductions)			Balance
		Beginning							at End
		of Period							of Period
	Allowance for Doubtful Accounts:
	Year ended December 31, 2013	$	26,257	$	37,392	$	(23,474	)	$	37,392
	Year ended December 31, 2012	$	29,473	$	9,659	$	(12,875	)	$	26,257
	Year ended December 31, 2011	$	23,231	$	8,527	$	(2,285	)	$	29,473
	Inventory Reserve:
	Year ended December 31, 2013	$	27,579	$	105,647	$	(98,217	)	$	35,009
	Year ended December 31, 2012	$	39,803	$	37,009	$	(49,233	)	$	27,579
	Year ended December 31, 2011	$	59,633	$	18,501	$	(38,332	)	$	39,803
	Deferred Tax Asset Valuation Allowance:
	Year ended December 31, 2013	$	38,266,000	$	18,006,000	$	—		$	56,272,000
	Year ended December 31, 2012	$	19,726,000	$	18,540,000	$	—		$	38,266,000
	Year ended December 31, 2011	$	11,963,000	$	7,763,000	$	—		$	19,726,000
	Allowances and reserves are deducted from the accounts to which they apply.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
Basis of Presentation	'
	Basis of Presentation
	Our consolidated financial statements include our accounts and the accounts for our wholly owned subsidiary, Rockwell Transportation, Inc.
	All intercompany balances and transactions have been eliminated in consolidation.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue at the time we transfer title to our products to our customers consistent with generally accepted accounting principles. Generally, we recognize revenue when our products are delivered to our customer's location consistent with our terms of sale. For international shipments, title generally transfers when the product is shipped.
	We require certain customers, mostly international customers, to pay for product prior to the transfer of title to the customer. Deposits received from customers and payments in advance for orders are recorded as liabilities under Customer Deposits until such time as orders are filled and title transfers to the customer consistent with our terms of sale. At December 31, 2013 and 2012 we had customer deposits of $207,545 and $135,133, respectively.
Shipping and Handling Revenue and Costs	'
	Shipping and Handling Revenue and Costs
	Our products are generally priced on a delivered basis with the price of delivery included in the overall price of our products which is reported as sales. Separately identified freight and handling charges are also included in sales.
	We include shipping and handling costs, including expenses of Rockwell Transportation, Inc., in cost of sales.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We consider cash on hand, money market funds and unrestricted certificates of deposit with an original maturity of 90 days or less as cash and cash equivalents.
Investments Available for Sale	'
	Investments Available for Sale
	Investments Available for Sale are short-term investments, consisting principally of investments in short term duration bond funds, and are stated at fair value based upon observed market prices (Level 1 in the fair value hierarchy). Unrealized holding gains or losses on these securities are included in accumulated other comprehensive income (loss). Realized gains and losses, including declines in value judged to be other-than-temporary on available-for-sale securities are included as a component of other income or expense.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable are stated at invoice amounts. The carrying amount of trade accounts receivable is reduced by an allowance for doubtful accounts that reflects our best estimate of accounts that may not be collected. We review outstanding trade accounts receivable balances and based on our assessment of expected collections, we estimate the portion, if any, of the balance that may not be collected as well as a general valuation allowance for other accounts receivable based primarily on historical experience. All accounts or portions thereof deemed to be uncollectible are written off to the allowance for doubtful accounts.
Inventory	'
	Inventory
	Inventory is stated at the lower of cost or net realizable value. Cost is determined on the first-in first-out (FIFO) method.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost. Expenditures for normal maintenance and repairs are charged to expense as incurred. Property and equipment are depreciated using the straight-line method over their useful lives, which range from three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of their useful lives or the related lease term.
Licensing Fees	'
	Licensing Fees
	License fees related to the technology, intellectual property and marketing rights for dialysate iron covered under certain issued patents have been capitalized and are being amortized over the life of the related patents which is generally 17 years.
Goodwill, Intangible Assets and Long Lived Assets	'
	Goodwill, Intangible Assets and Long Lived Assets
	The recorded amounts of goodwill and other intangibles from prior business combinations are based on management's best estimates of the fair values of assets acquired and liabilities assumed at the date of acquisition. Goodwill is not amortized; however, it must be tested for impairment at least annually. Amortization continues to be recorded for other intangible assets with definite lives over their estimated useful lives. Intangible assets subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable.
	An impairment review of goodwill, intangible assets, and property and equipment is performed annually or whenever a change in condition occurs which indicates that the carrying amounts of assets may not be recoverable. Such changes may include changes in our business strategies and plans, changes to our customer contracts, changes to our product lines and changes in our operating practices. We use a variety of factors to assess the realizable value of long-lived assets depending on their nature and use.
	The useful lives of other intangible assets are based on management's best estimates of the period over which the assets are expected to contribute directly or indirectly to our future cash flows. Management annually evaluates the remaining useful lives of intangible assets with finite useful lives to determine whether events and circumstances warrant a revision to the remaining amortization periods. It is reasonably possible that management's estimates of the carrying amount of goodwill and the remaining useful lives of other intangible assets may change in the near term.
Debt Issuance Costs	'
	Debt Issuance Costs
	Debt issuance costs are capitalized and amortized over the term of the underlying debt instruments using the effective-interest rate method. Debt issuance costs are recorded as other assets.
Income Taxes	'
	Income Taxes
	We account for income taxes in accordance with the provisions of ASC 740-10, Income Taxes. A current tax liability or asset is recognized for the estimated taxes payable or refundable on tax returns for the year. Deferred tax liabilities or assets are recognized for the estimated future tax effects of temporary differences between book and tax accounting and operating loss and tax credit carryforwards. A valuation allowance is established for deferred tax assets if we determine it to be more likely than not that the deferred tax asset will not be realized. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as income tax expense.
	The effects of tax positions are generally recognized in the financial statements consistent with amounts reflected in returns filed, or expected to be filed, with taxing authorities. For tax positions that the Company considers to be uncertain, current and deferred tax liabilities are recognized, or assets derecognized, when it is probable that an income tax liability has been incurred and the amount of the liability is reasonably estimable, or when it is probable that a tax benefit, such as a tax credit or loss carryforward, will be disallowed by a taxing authority. The amount of unrecognized tax benefits related to tax positions is insignificant.
Research and Product Development	'
	Research and Product Development
	We recognize research and product development costs as expenses as incurred. We incurred product development and research costs related to the commercial development, patent approval and regulatory approval of new products, including Triferic®, aggregating approximately $39,382,000, $48,272,000, and $17,805,000 in 2013, 2012 and 2011, respectively.
Share Based Compensation	'
	Share Based Compensation
	We measure the cost of employee services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards in accordance with ASC 718-10, Compensation—Stock Compensation. The cost of equity based compensation is recognized as compensation expense over the vesting period of the awards.
	We estimate the fair value of compensation involving stock options utilizing the Black-Scholes option pricing model. This model requires the input of several factors such as the expected option term, expected volatility of our stock price over the expected option term, and an expected forfeiture rate, and is subject to various assumptions. We believe the valuation methodology is appropriate for estimating the fair value of stock options we grant to employees and directors which are subject to ASC 718-10 requirements. These amounts are estimates and thus may not be reflective of actual future results or amounts ultimately realized by recipients of these grants.
Employee Retirement Plans	'
	Employee Retirement Plans
	We are the sponsor of a non-contributory 401(k) Employee Savings Plan.
Earnings per Share	'
	Earnings per Share
	We computed our basic earnings (loss) per share using weighted average shares outstanding for each respective period. Diluted earnings per share also reflect the weighted average impact from the date of issuance of all potentially dilutive securities, consisting of stock options and common share purchase warrants, unless inclusion would have had an anti-dilutive effect. Actual weighted average shares outstanding used in calculating basic and diluted earnings per share were:
		2013			2012		2011
	Basic Weighted Average Shares Outstanding		32,882,333			20,395,889		17,774,865
	Effect of Dilutive Securities		-0-			-0-		-0-
	Diluted Weighted Average Shares Outstanding		32,882,333			20,395,889		17,774,865
	For 2013, 2012 and 2011, the dilutive effect of stock options and common share purchase warrants have not been included in the average shares outstanding for the calculation of diluted loss per share as the effect would be anti-dilutive as a result of our net loss in these periods. The table below summarizes potentially dilutive securities.
		2013		2012		2011
	Stock Options	6,228,000		5,989,200		5,482,135
	Range of Exercise Prices of Stock Options	$2.79 - $11.44		$1.81 - $10.20		$0.55 - $10.20
	Common Share Purchase Warrants	983,071		2,233,240		2,607,440
	Range of Exercise Prices of Warrants	$9.55 - $10.25		$6.14 - $10.25		$6.14 - $10.25
	Unvested Restricted Common Shares	545,000		545,000		310,000
Other Comprehensive Income (Loss)	'
	Other Comprehensive Income (Loss)
	Accounting principles generally require that recognized revenue, expenses, gains, and losses be included in net income. Certain changes in assets and liabilities, however, such as unrealized gains and losses on available for sale securities, are reported as a direct adjustment to the equity section of the balance sheet. Such items, along with net income (loss), are considered components of comprehensive income (loss). Accumulated Other Comprehensive Income (Loss) consists solely of unrealized gains and losses on available-for-sale investment securities.
Estimates in Preparation of Financial Statements	'
	Estimates in Preparation of Financial Statements
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
Schedule of weighted average shares outstanding used in calculating basic and diluted earnings per share	'
		2013			2012		2011
	Basic Weighted Average Shares Outstanding		32,882,333			20,395,889		17,774,865
	Effect of Dilutive Securities		-0-			-0-		-0-
	Diluted Weighted Average Shares Outstanding		32,882,333			20,395,889		17,774,865
Summary of potentially dilutive securities	'
		2013		2012		2011
	Stock Options	6,228,000		5,989,200		5,482,135
	Range of Exercise Prices of Stock Options	$2.79 - $11.44		$1.81 - $10.20		$0.55 - $10.20
	Common Share Purchase Warrants	983,071		2,233,240		2,607,440
	Range of Exercise Prices of Warrants	$9.55 - $10.25		$6.14 - $10.25		$6.14 - $10.25
	Unvested Restricted Common Shares	545,000		545,000		310,000

FAIR_MARKET_VALUE_MEASUREMENTS1

FAIR MARKET VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Market Value Measurements	'
Schedule of carrying value and fair value of financial instruments other than trade receivables and payables	'
	Based on the foregoing methods and assumptions, the carrying value and fair value of the Company's financial instruments other than trade receivables and payables are as follows (in thousands):
		Carrying		Fair value		Level 1		Level 2		Level 3
		value
	As of December 31, 2013
	Financial assets
	Cash and cash equivalents	$	11,881	$	11,881	$	11,811	$	—	$	—
	Investment securities available for sale		12,035		12,035		12,035		—		—
	Financial liabilities
	Notes Payable		20,000		20,000		—		20,000		—
	As of December 31, 2012
	Financial assets
	Cash and cash equivalents		4,712		4,712		4,712		—		—
	Investment securities available for sale		—		—		—		—		—
	Financial liabilities
	Notes Payable		—		—		—		—		—

INVENTORY_Tables

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2013
INVENTORY	'
Schedule components of inventory	'
		2013		2012
	Raw Materials	$	1,142,776	$	1,018,648
	Work in Process		254,714		179,922
	Finished Goods		1,402,158		1,451,069
	Total	$	2,799,648	$	2,649,639

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
PROPERTY AND EQUIPMENT	'
Schedule of major classes of property and equipment, stated at cost	'
		2013			2012
	Leasehold Improvements	$	517,907		$	463,080
	Machinery and Equipment		6,398,366			6,046,055
	Information Technology & Office Equipment		1,961,968			1,911,493
	Laboratory Equipment		513,616			505,883
	Transportation Equipment		374,035			383,711
			9,765,922			9,310,222
	Accumulated Depreciation		(8,116,973	)		(7,451,780	)
	Net Property and Equipment	$	1,648,949		$	1,858,442
Summary of depreciation expense	'
		2013			2012			2011
	Depreciation expense	$	840,382		$	920,368		$	1,141,545

GOODWILL_AND_INTANGIBLE_ASSETS1

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
GOODWILL AND INTANGIBLE ASSETS	'
Schedule of costs are being amortized	'
		2013			2012			2011
	Capitalized Licensing Fees	$	1,070,126		$	1,070,126		$	1,070,126
	Accumulated Amortization		(570,411	)		(403,382	)		(236,353	)
	Capitalized Licensing Fees, Net of Amortization	$	499,715		$	666,744		$	833,773
	Amortization Expense	$	167,029		$	167,029		$	28,005

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2013
NOTES PAYABLE	'
Schedule of debt maturity	'
	2014	$	2,308,145
	2015		7,544,935
	2016		8,555,035
	2017		1,591,885
	Total Principal Payable	$	20,000,000

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2013
ACCRUED LIABILITIES	'
Schedule of accrued liabilities	'
		2013		2012
	Accrued Research & Development Expense	$	3,237,093	$	9,832,357
	Accrued Compensation and Benefits		1,490,953		1,118,475
	Other Accrued Liabilities		1,919,782		1,065,146
	Total Accrued Liabilities	$	6,647,828	$	12,015,978

OPERATING_LEASES_Tables

OPERATING LEASES (Tables)	12 Months Ended
	Dec. 31, 2013
OPERATING LEASES	'
Rent Expense Recognized Under Operating Leases	'
		2013		2012		2011
	Rent Expense Recognized Under Operating Leases	$	2,163,281	$	1,955,626	$	2,001,094
Schedule of future minimum rental payments under operating lease agreements	'
	Year ending December 31, 2014	$	1,500,697
	Year ending December 31, 2015		1,163,791
	Year ending December 31, 2016		765,542
	Year ending December 31, 2017		740,058
	Year ending December 31, 2018		732,079
	Year ending December 31, 2019 and thereafter		599,559
	Total	$	5,501,726

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
INCOME TAXES	'
Schedule of reconciliation of income tax expense at the statutory rate to income tax expense at Entity's effective tax rate	'
		2013			2012			2011
	Tax Expense Computed at 34% of Pretax Income	$	(16,583,000	)	$	(18,367,000	)	$	(7,291,000	)
	State Income Taxes		—			—			2,005
	Effect of Change in Valuation Allowance		(16,583,000	)		(18,367,000	)		(7,291,000	)
	Total Income Tax Expense	$	-0-		$	-0-		$	2,005
Schedule of details of the net deferred tax asset	'
		December 31,
		2013			2012
	Deferred tax assets:
	Net Operating Loss Carryforward	$	49,426,000		$	33,016,000
	Stock Based Compensation		6,839,000			5,398,000
	Accrued Expenses		334,000			274,000
	Inventories		65,000			66,000
	Prepaid Expenses		—			51,000
	Workers' Compensation Reserve		60,000			—
	Accounts Receivable		13,000			9,000
	Total Deferred Tax Assets		56,737,000			38,814,000
	Deferred Tax Liabilities:
	Tax over Book Depreciation		118,000			276,000
	Goodwill & Intangible Assets		225,000			272,000
	Prepaid Expenses		122,000			—
	Total Deferred Tax Liabilities		465,000			548,000
	Subtotal		56,272,000			38,266,000
	Valuation Allowance		(56,272,000	)		(38,266,000	)
	Net Deferred Tax Asset	$	-0-		$	-0-

CAPITAL_STOCK_Tables

CAPITAL STOCK (Tables)	12 Months Ended
	Dec. 31, 2013
CAPITAL STOCK	'
Summary of capital stock share issuances	'
		2013			2012			2011
	Shares outstanding as of December 31,		40,110,661			21,494,696			18,710,002
	Summary of Share Issuances:
	Shares Issuances related to Equity Compensation:
	Shares issued upon exercise of stock options by employees		478,411			216,477			397,054
	Proceeds realized from stock option exercises	$	766,926		$	132,026		$	719,484
	Average exercise price of options exercised	$	1.6		$	0.61		$	1.81
	Restricted Stock Grants		310,000			235,000			—
	Share issuances related to Warrant Exercises
	Shares issued upon the exercise of warrants		130,833			288,217			799,340
	Proceeds realized from warrant exercises	$	1,164,982		$	1,982,720		$	3,877,276
	Share issuances related to Equity Offerings
	Shares issued pursuant to equity offerings		17,496,721			1,845,000
	Proceeds realized from equity offerings	$	49,664,324		$	16,120,669
	Share issuances in Exchange for Services
	Share issuances in Exchange for Services		200,000			200,000
	Value of Shares issued in Exchange for Services	$	780,678		$	1,854,000
Schedule of outstanding warrants by exercise price	'
	Exercise Price	Expiration Date		2013			2012			2011
	$9.55	10/5/14			883,071			883,071			883,071
	$10.25	3/31/14			100,000			100,000			100,000
	$7.18	1/28/13			—			1,059,169			1,079,169
	$8.00	5/28/13			—			104,000			105,000
	$10.00	11/28/13			—			80,000			80,000
	$6.14	3/8/13			—			7,000			15,000
	$7.00	5/4/12			—			—			200,000
	$9.55	10/5/12			—			—			85,200
	$6.50	9/30/12			—			—			60,000
	Total				983,071			2,233,240			2,607,440

LONG_TERM_INCENTIVE_PLAN_STOCK1

LONG TERM INCENTIVE PLAN & STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2013
LONG TERM INCENTIVE PLAN & STOCK OPTIONS	'
Schedule of restricted shares	'
		2013			2012			2011
	Restricted Shares Granted		310,000			235,000			—
	Market Value Per Share on Grant Date	$	3.94		$	9.45
	Expense related to All Restricted Shares	$	1,961,501		$	1,075,929		$	596,000
	Unearned Stock Based Compensation for All Restricted Stock Awards Attributable to Future Periods.	$	1,147,935
Summary of the status of the LTIP and the Old Plan	'
		SHARES			WEIGHTED			AGGREGATE
					AVERAGE			INTRINSIC
					EXERCISE			VALUE
					PRICE
	Outstanding at December 31, 2010		5,289,334			4.52		$	17,879,160
	Granted		839,000			8.54
	Exercised		(416,201	)		1.81		$	2,571,874
	Forfeited		(229,998	)		6.61
	Outstanding at December 31, 2011		5,482,135			5.23		$	17,761,008
	Granted		871,000			9.62
	Exercised		(223,601	)		0.59		$	1,486,470
	Forfeited		(140,334	)		8.66
	Outstanding at December 31, 2012		5,989,200			5.95		$	12,559,074
	Granted		920,500			5.74
	Exercised		(623,700	)		1.23		$	1,920,557
	Forfeited		(58,000	)		8.31
	Outstanding at December 31, 2013		6,228,000			6.27		$	25,956,880
Schedule of options outstanding and options exercisable by range of exercise prices	'
	OPTIONS OUTSTANDING									OPTIONS EXERCISABLE
	RANGE OF EXERCISE PRICES	NUMBER OF			REMAINING		WEIGHTED			NUMBER OF		WEIGHTED
		OPTIONS			CONTRACTUAL		EXERCISE			OPTIONS		AVERAGE
					LIFE		PRICE					EXERCISE
												PRICE
	$2.79 to $4.98		1,894,600		0.2 - 9.6 yrs.		$	3.71			1,759,100	$	3.72
	$5.34 to $7.13		2,799,400		3.8 - 9.7 yrs.		$	6.43			2,010,467	$	6.56
	$8.35 to 11.44		1,534,000		5.8 - 9.8 yrs.		$	9.15			744,000	$	8.94
	Total		6,228,000		5.6 yrs.		$	6.27			4,513,567	$	5.85
	Intrinsic Value	$	25,956,880							$	20,726,770
Schedule of unvested options	'
		NUMBER OF			WEIGHTED
		UNVESTED			AVERAGE
		OPTIONS			FAIR MARKET
					VALUE AT
					GRANT DATE
	As of December 31, 2010		1,609,111
	Granted		839,000		$	5.06
	Forfeited		(229,998	)
	Vested		(688,780	)
	As of December 31, 2011		1,529,333
	Granted		871,000		$	5.93
	Forfeited		(140,334	)
	Vested		(680,999	)
	As of December 31, 2012		1,579,000
	Granted		920,500		$	3.33
	Forfeited		(58,000	)
	Vested		(727,067	)
	As of December 31, 2013		1,714,433
Schedule of assumptions used in stock option valuation	'
		2013		2012		2011
	Volatility of share price	59 - 67%		64 - 65%		63 - 64%
	Risk free interest rate	0.1 - 2.0%		0.8 - 1.2%		1.1 - 2.6%
	Expected option life	1 - 6 yrs.		6 yrs.		6 yrs.
	Dividend Yield	0.00%		0.00%		0.00%

QUARTERLY_RESULTS_OF_OPERATION1

QUARTERLY RESULTS OF OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2013
QUARTERLY RESULTS OF OPERATIONS	'
Summary of the quarterly results of operations	'
		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	2013
	Sales	$	12,336,374		$	12,984,164		$	13,094,381		$	13,964,624
	Cost of Sales		11,055,394			11,299,099			11,461,100			11,904,730
	Gross Profit		1,280,980			1,685,065			1,633,281			2,059,894
	Selling, General and Administrative		3,916,783			3,237,974			3,386,367			3,795,325
	Research and Product Development		12,754,518			10,222,721			10,611,219			5,793,579
	Operating Income (Loss)		(15,390,321	)		(11,775,630	)		(12,364,305	)		(7,529,010	)
	Interest and Investment Income, net		10,672			4,566			13,546			69,317
	Interest Expense		75			92,155			857,505			872,412
	Income (Loss) Before Income Taxes		(15,379,724	)		(11,863,219	)		(13,208,264	)		(8,332,105	)
	Income Tax Expense		—			—			—			—
	Net Income (Loss)	$	(15,379,724	)	$	(11,863,219	)	$	(13,208,264	)	$	(8,332,105	)
	Basic And Diluted Earnings (Loss) Per Share	$	(.72	)	$	(.38	)	$	(.34	)	$	(.21	)
		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	2012
	Sales	$	12,028,417		$	12,124,790		$	12,689,339		$	12,999,846
	Cost of Sales		10,401,941			10,405,991			11,043,412			11,297,621
	Gross Profit		1,626,476			1,718,799			1,645,927			1,702,225
	Selling, General and Administrative		2,898,684			2,824,379			3,325,411			3,635,386
	Research and Product Development		9,405,547			10,876,396			16,238,450			11,751,256
	Operating Income (Loss)		(10,677,755	)		(11,981,976	)		(17,917,934	)		(13,684,417	)
	Interest and Investment Income, net		111,097			77,091			42,296			11,034
	Interest Expense		253			456			137			105
	Income (Loss) Before Income Taxes		(10,566,911	)		(11,905,341	)		(17,875,775	)		(13,673,488	)
	Income Tax Expense		—			—			—			—
	Net Income (Loss)	$	(10,566,911	)	$	(11,905,341	)	$	(17,875,775	)	$	(13,673,488	)
	Basic And Diluted Earnings (Loss) Per Share	$	(.54	)	$	(.58	)	$	(.86	)	$	(.66	)

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue Recognition	'	'	'	'	'	'	'	'	'	'	'
Customer Deposits	$207,545	'	'	'	$135,133	'	'	'	$207,545	$135,133	'
Research and Product Development	'	'	'	'	'	'	'	'	'	'	'
Product development and research costs	$5,793,579	$10,611,219	$10,222,721	$12,754,518	$11,751,256	$16,238,450	$10,876,396	$9,405,547	$39,382,037	$48,271,649	$17,805,362
Patents	'	'	'	'	'	'	'	'	'	'	'
Summary of significant accounting policies	'	'	'	'	'	'	'	'	'	'	'
Useful life	'	'	'	'	'	'	'	'	'17 years	'	'
Minimum	'	'	'	'	'	'	'	'	'	'	'
Summary of significant accounting policies	'	'	'	'	'	'	'	'	'	'	'
Useful lives	'	'	'	'	'	'	'	'	'3 years	'	'
Maximum	'	'	'	'	'	'	'	'	'	'	'
Summary of significant accounting policies	'	'	'	'	'	'	'	'	'	'	'
Useful lives	'	'	'	'	'	'	'	'	'10 years	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Weighted average shares outstanding used in calculating basic and diluted earnings per share	'	'	'
Basic Weighted Average Shares Outstanding	32,882,333	20,395,889	17,774,865
Effect of Dilutive Securities	0	0	0
Diluted Weighted Average Shares Outstanding	32,882,333	20,395,889	17,774,865
Stock options	'	'	'
Net Earnings per Share	'	'	'
Securities excluded from diluted loss per share calculation	6,228,000	5,989,200	5,482,135
Stock options | Minimum	'	'	'
Net Earnings per Share	'	'	'
Exercisable price (in dollars per share)	2.79	1.81	0.55
Stock options | Maximum	'	'	'
Net Earnings per Share	'	'	'
Exercisable price (in dollars per share)	11.44	10.2	10.2
Common share purchase warrants	'	'	'
Net Earnings per Share	'	'	'
Securities excluded from diluted loss per share calculation	983,071	2,233,240	2,607,440
Common share purchase warrants | Minimum	'	'	'
Net Earnings per Share	'	'	'
Exercise price (in dollars per share)	9.55	6.14	6.14
Common share purchase warrants | Maximum	'	'	'
Net Earnings per Share	'	'	'
Exercise price (in dollars per share)	10.25	10.25	10.25
Restricted common shares	'	'	'
Net Earnings per Share	'	'	'
Securities excluded from diluted loss per share calculation	545,000	545,000	310,000

FAIR_MARKET_VALUE_MEASUREMENTS2

FAIR MARKET VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Financial assets	'	'
Investment securities available for sale	'	$14,037,255
Carrying value	'	'
Financial assets	'	'
Cash and cash equivalents	11,881,000	4,712,000
Investment securities available for sale	12,035,000	'
Financial liabilities	'	'
Notes Payable	20,000,000	'
Fair value	'	'
Financial assets	'	'
Cash and cash equivalents	11,881,000	4,712,000
Investment securities available for sale	12,035,000	'
Financial liabilities	'	'
Notes Payable	20,000,000	'
Level 1	'	'
Financial assets	'	'
Cash and cash equivalents	11,811,000	4,712,000
Investment securities available for sale	12,035,000	'
Level 2	'	'
Financial liabilities	'	'
Notes Payable	$20,000,000	'

INVESTMENTS_IN_AVAILABLE_FOR_S1

INVESTMENTS IN AVAILABLE FOR SALE SECURITIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
INVESTMENTS IN AVAILABLE FOR SALE SECURITIES	'	'	'
Market value of investments	$12,034,622	'	'
Market value of securities purchased	12,002,203	2,012,671	2,000,000
Unrealized gains	44,070	'	'
Unrealized losses	11,652	'	'
Market value of securities sold	'	14,037,255	'
Average cost basis	'	14,104,558	'
Realized gains	'	10,436	'
Realized losses	'	$77,739	'

SIGNIFICANT_MARKET_SEGMENTS_De

SIGNIFICANT MARKET SEGMENTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
SIGNIFICANT MARKET SEGMENTS	'	'	'
Number of operating market segment	1	'	'
Significant market segments	'	'	'
Accounts receivable	4,578,319	4,431,932	'
Assets	36,362,124	17,025,086	'
Outside United States	'	'	'
Significant market segments	'	'	'
Assets	0	'	'
Sales | Foreign customers and distributors | Maximum	'	'	'
Significant market segments	'	'	'
Concentration risk (as a percent)	5.00%	5.00%	5.00%
Sales | Total international sales, including sales to domestic distributors	'	'	'
Significant market segments	'	'	'
Concentration risk (as a percent)	12.00%	11.00%	13.00%
Sales | Customer concentration	'	'	'
Significant market segments	'	'	'
Customers accounted for more than 10% of sales	0	0	0
DaVita Healthcare Partners, Inc. | Customer concentration	'	'	'
Significant market segments	'	'	'
Number of customers	1	'	'
Accounts receivable	1,886,000	2,352,000	'
DaVita Healthcare Partners, Inc. | Sales | Customer concentration	'	'	'
Significant market segments	'	'	'
Concentration risk (as a percent)	49.00%	49.00%	48.00%

INVENTORY_Details

INVENTORY (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
INVENTORY	'	'
Raw Materials	$1,142,776	$1,018,648
Work in Process	254,714	179,922
Finished Goods	1,402,158	1,451,069
Total	$2,799,648	$2,649,639

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and equipment	'	'	'
Gross Property and Equipment	$9,765,922	$9,310,222	'
Accumulated Depreciation	-8,116,973	-7,451,780	'
Net Property and Equipment	1,648,949	1,858,442	'
Depreciation expense	840,382	920,368	1,141,545
Leasehold Improvements	'	'	'
Property and equipment	'	'	'
Gross Property and Equipment	517,907	463,080	'
Machinery and Equipment	'	'	'
Property and equipment	'	'	'
Gross Property and Equipment	6,398,366	6,046,055	'
Information Technology & Office Equipment	'	'	'
Property and equipment	'	'	'
Gross Property and Equipment	1,961,968	1,911,493	'
Laboratory Equipment	'	'	'
Property and equipment	'	'	'
Gross Property and Equipment	513,616	505,883	'
Transportation Equipment	'	'	'
Property and equipment	'	'	'
Gross Property and Equipment	$374,035	$383,711	'

GOODWILL_AND_INTANGIBLE_ASSETS2

GOODWILL AND INTANGIBLE ASSETS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
GOODWILL AND INTANGIBLE ASSETS	'	'	'
Total goodwill	$920,745	$920,745	'
Adjustment for impairment of goodwill	0	0	'
Estimated amortization expense	'	'	'
2014	167,000	'	'
2015	167,000	'	'
2016	167,000	'	'
Global licensing agreement	'	'	'
Intangible assets	'	'	'
Capitalized Licensing Fees	1,070,126	1,070,126	1,070,126
Accumulated Amortization	-570,411	-403,382	-236,353
Capitalized Licensing Fees, Net of Amortization	499,715	666,744	833,773
Amortization expense	167,029	167,029	28,005
ANDA	'	'	'
Intangible assets	'	'	'
Amortization period	'5 years	'	'
Capitalized Licensing Fees, Net of Amortization	'	'	$695,000

OTHER_CURRENT_ASSETS_Details

OTHER CURRENT ASSETS (Details) (USD $)	Dec. 31, 2012
OTHER CURRENT ASSETS	'
Advances classified as other current assets	$852,555

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Notes payable	'
Debt issuance costs	$1,109,776
Loan Agreement	'
Notes payable	'
Aggregate principal amount	20,000,000
Number of installments over which the loan is to be repaid	30
Maturity date	1-Mar-17
Interest rate under second condition (as a percent)	12.50%
Debt issuance costs	1,100,000
Fee paid to Hercules	200,000
Fee due and accrued	1,100,000
Effective interest rate of loan (as a percent)	14.50%
Maturities of debt	'
2014	2,308,145
2015	7,544,935
2016	8,555,035
2017	1,591,885
Total Principal Payable	20,000,000
Loan Agreement | Forecast	'
Notes payable	'
Fee paid to Hercules	$1,100,000
Loan Agreement | Prime rate	'
Notes payable	'
Spread added to reference rate under first condition (as a percent)	12.50%
Variable rate basis under first condition	'prime rate
Percentage point deducted from reference rate to compute variable rate under first condition	3.25%

ACCRUED_LIABILITIES_Details

ACCRUED LIABILITIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
ACCRUED LIABILITIES	'	'
Accrued Research & Development Expense	$3,237,093	$9,832,357
Accrued Compensation and Benefits	1,490,953	1,118,475
Other Accrued Liabilities	1,919,782	1,065,146
Total Accrued Liabilities	$6,647,828	$12,015,978

OPERATING_LEASES_Details

OPERATING LEASES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	sqft
OPERATING LEASES	'	'	'
Area occupied by Entity (in square feet)	51,000	'	'
Rent Expense Recognized Under Operating Leases	$2,163,281	$1,955,626	$2,001,094
Future minimum rental payments under operating lease agreements	'	'	'
Year ending December 31, 2014	1,500,697	'	'
Year ending December 31, 2015	1,163,791	'	'
Year ending December 31, 2016	765,542	'	'
Year ending December 31, 2017	740,058	'	'
Year ending December 31, 2018	732,079	'	'
Year ending December 31, 2019 and thereafter	599,559	'	'
Total	$5,501,726	'	'
Maximum	'	'	'
OPERATING LEASES	'	'	'
Lease term	'7 years	'	'
Michigan	'	'	'
OPERATING LEASES	'	'	'
Area occupied by Entity (in square feet)	17,500	'	'
Texas	'	'	'
OPERATING LEASES	'	'	'
Area occupied by Entity (in square feet)	51,000	'	'
South Carolina	'	'	'
OPERATING LEASES	'	'	'
Area occupied by Entity (in square feet)	57,000	'	'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
INCOME TAXES	'	'	'
Statutory rate (as a percent)	34.00%	'	'
Reconciliation of income tax expense at the statutory rate to income tax expense at Entity's effective tax rate	'	'	'
Tax Expense Computed at 34 % of Pretax Income	($16,583,000)	($18,367,000)	($7,291,000)
State Income Taxes	'	'	2,005
Effect of Change in Valuation Allowance	-16,583,000	-18,367,000	-7,291,000
Total Income Tax Expense	0	'	2,005
Deferred tax assets:	'	'	'
Net Operating Loss Carryforward	49,426,000	33,016,000	'
Stock Based Compensation	6,839,000	5,398,000	'
Accrued Expenses	334,000	274,000	'
Inventories	65,000	66,000	'
Prepaid Expenses	'	51,000	'
Workers' Compensation Reserve	60,000	'	'
Accounts Receivable	13,000	9,000	'
Total Deferred Tax Assets	56,737,000	38,814,000	'
Deferred Tax Liabilities:	'	'	'
Tax over Book Depreciation	118,000	276,000	'
Goodwill & Intangible Assets	225,000	272,000	'
Prepaid Expenses	122,000	'	'
Total Deferred Tax Liabilities	465,000	548,000	'
Subtotal	56,272,000	38,266,000	'
Valuation Allowance	-56,272,000	-38,266,000	'
Net Deferred Tax Asset	0	0	'
Net operating loss carryforwards	145,371,000	'	'
Excess tax benefits on share based compensation that would be credited directly to contributed capital, if recognized	$3,700,000	'	'

CAPITAL_STOCK_Details

CAPITAL STOCK (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	item
CAPITAL STOCK	'	'	'
Preferred Shares, shares authorized	2,000,000	2,000,000	2,000,000
Preferred Shares, shares issued	0	0	0
Preferred Shares, shares outstanding	0	0	0
Common Shares, shares authorized	120,000,000	120,000,000	120,000,000
Common Shares, shares outstanding	40,110,661	21,494,696	18,710,002
Common Shares, par value (in dollars per share)	$0	$0	$0
Shares Issuances related to Equity Compensation:	'	'	'
Shares issued upon exercise of stock options by employees	478,411	216,477	397,054
Proceeds realized from stock option exercises (in dollars)	$766,926	$132,026	$719,484
Average exercise price of options exercised (in dollars per share)	$1.60	$0.61	$1.81
Restricted Stock Grants (in shares)	310,000	235,000	'
Share issuances related to Warrant Exercises	'	'	'
Shares issued upon the exercise of warrants	130,833	288,217	799,340
Proceeds realized from warrant exercises (in dollars)	-1,164,982	-1,978,729	-3,877,276
Share issuances related to Equity Offerings	'	'	'
Shares issued pursuant to equity offerings	17,496,721	1,845,000	'
Proceeds realized from equity offerings (in dollars)	49,664,324	16,120,669	'
Share issuances in Exchange for Services	'	'	'
Share issuances in Exchange for Services	200,000	200,000	'
Value of Shares issued in Exchange for Services (in dollars)	$780,678	$1,854,000	'
Number of votes per common share	1	'	'

CAPITAL_STOCK_Details_2

CAPITAL STOCK (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Warrants	'	'	'
Outstanding common share purchase warrants	983,071	2,233,240	2,607,440
Exercisable common share purchase warrants	983,071	2,133,240	2,507,440
Expense recognized related to services and consideration provided in exchange for warrants	$1,082,196	$468,417	$312,000
$9.55	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	883,071	883,071	883,071
Exercise price (in dollars per share)	$9.55	'	'
$10.25	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	100,000	100,000	100,000
Exercise price (in dollars per share)	$10.25	'	'
$7.18	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	'	1,059,169	1,079,169
Exercise price (in dollars per share)	$7.18	'	'
$8.00	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	'	104,000	105,000
Exercise price (in dollars per share)	$8	'	'
$10.00	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	'	80,000	80,000
Exercise price (in dollars per share)	$10	'	'
$6.14	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	'	7,000	15,000
Exercise price (in dollars per share)	$6.14	'	'
$7.00	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	'	'	200,000
Exercise price (in dollars per share)	$7	'	'
$9.55	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	'	'	85,200
Exercise price (in dollars per share)	$9.55	'	'
$6.50	'	'	'
Warrants	'	'	'
Outstanding common share purchase warrants	'	'	60,000
Exercise price (in dollars per share)	$6.50	'	'
Warrants expiring on January 28, 2013	'	'	'
Warrants	'	'	'
Number of warrants whose term is changed (in shares)	'	1,079,169	'
Expense recognized due to change in term of warrants	'	280,600	'
Warrants expiring on November 28, 2013	'	'	'
Warrants	'	'	'
Number of warrants whose term is changed (in shares)	'	80,000	'
Expense recognized due to change in term of warrants	'	33,600	'
Warrants expiring on March 31, 2014	'	'	'
Warrants	'	'	'
Issuance of common share purchase warrants	'	'	100,000
Exercise price (in dollars per share)	'	'	$10.25
Warrants issued in November 2008	'	'	'
Warrants	'	'	'
Number of warrants whose term is changed (in shares)	'	'	245,000
Expense recognized due to change in term of warrants	'	'	165,850
Warrants expiring on July 31, 2013	'	'	'
Warrants	'	'	'
Number of warrants whose term is changed (in shares)	1,008,336	'	'
Expense recognized due to change in term of warrants	$927,669	'	'

LONG_TERM_INCENTIVE_PLAN_STOCK2

LONG TERM INCENTIVE PLAN & STOCK OPTIONS (Details) (USD $)

12 Months Ended

12 Months Ended

84 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Options

Options

Options

Options

LTIP

LTIP

LTIP

LTIP

LTIP

LTIP

LTIP

LTIP

LTIP

Old Plan

Options

Options

Options

Restricted shares

Restricted shares

Restricted shares

Restricted shares

Restricted shares

2012 grant

2013 grant

LONG TERM INCENTIVE PLAN & STOCK OPTIONS

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common shares reserved for issuance

'

'

'

'

'

'

'

7,750,000

'

'

'

'

'

'

'

'

'

Options granted (in shares)

'

'

'

920,500

871,000

839,000

'

'

'

'

'

'

'

'

'

'

0

Expiration term

'

'

'

'10 years

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

Vesting period

'

'

'

'3 years

'

'

'

'

'3 years

'

'

'

'

'

'2 years

'14 months

'

Additional disclosures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Shares Granted

310,000

235,000

'

'

'

'

'

'

'

'

'

310,000

235,000

'

'

'

'

Market Value Per Share on Grant Date

'

'

'

'

'

'

'

'

'

'

'

$3.94

$9.45

'

'

'

'

Expense related to All Restricted Shares

'

'

'

'

'

'

'

'

$3,877,695

$3,903,795

$3,469,703

$1,961,501

$1,075,929

$596,000

'

'

'

Unearned Stock Based Compensation for All Restricted Stock Awards Attributable to Future Periods

'

'

'

'

'

'

'

'

'

'

'

1,147,935

'

'

'

'

'

Minimum period for which previously issued shares are to be held by the recipient for non-cash exchange to newly issued shares

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash proceeds received upon the exercise of options

766,926

132,026

719,484

766,926

132,026

719,484

'

'

'

'

'

'

'

'

'

'

'

Income tax benefits related to stock option activity

609,000

494,000

772,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Excess tax benefits on share based compensation that would be credited directly to contributed capital, if recognized

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

SHARES

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the beginning of the period (in shares)

'

'

'

5,989,200

5,482,135

5,289,334

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

'

920,500

871,000

839,000

'

'

'

'

'

'

'

'

'

'

0

Exercised (in shares)

'

'

'

-623,700

-223,601

-416,201

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in shares)

'

'

'

-58,000

-140,334

-229,998

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the end of the period (in shares)

'

'

'

6,228,000

5,989,200

5,482,135

'

'

'

'

'

'

'

'

'

'

'

WEIGHTED AVERAGE EXERCISE PRICE

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the beginning of the period (in dollars per share)

'

'

'

$5.95

$5.23

$4.52

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

$5.74

$9.62

$8.54

'

'

'

'

'

'

'

'

'

'

'

Exercised (in dollars per share)

$1.60

$0.61

$1.81

$1.23

$0.59

$1.81

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in dollars per share)

'

'

'

$8.31

$8.66

$6.61

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the end of the period (in dollars per share)

'

'

'

$6.27

$5.95

$5.23

'

'

'

'

'

'

'

'

'

'

'

AGGREGATE INTRINSIC VALUE

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in dollars)

25,956,880

'

'

25,956,880

12,559,074

17,761,008

17,879,160

'

'

'

'

'

'

'

'

'

'

Exercised (in dollars)

'

'

'

$1,920,557

$1,486,470

$2,571,874

'

'

'

'

'

'

'

'

'

'

'

LONG_TERM_INCENTIVE_PLAN_STOCK3

LONG TERM INCENTIVE PLAN & STOCK OPTIONS (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013
OPTIONS OUTSTANDING	'
NUMBER OF OPTIONS (in shares)	6,228,000
REMAINING CONTRACTUAL LIFE	'5 years 7 months 6 days
WEIGHTED EXERCISE PRICE (in dollars per share)	$6.27
Intrinsic Value (in dollars)	$25,956,880
OPTIONS EXERCISABLE	'
NUMBER OF OPTIONS (in shares)	4,513,567
WEIGHTED EXERCISE PRICE (in dollars per share)	$5.85
Intrinsic Value (in dollars)	$20,726,770
$ 2.79 to $4.98	'
LONG TERM INCENTIVE PLAN & STOCK OPTIONS	'
Exercise price, low end of range (in dollars per share)	$2.79
Exercise price, high end of range (in dollars per share)	$4.98
OPTIONS OUTSTANDING	'
NUMBER OF OPTIONS (in shares)	1,894,600
WEIGHTED EXERCISE PRICE (in dollars per share)	$3.71
OPTIONS EXERCISABLE	'
NUMBER OF OPTIONS (in shares)	1,759,100
WEIGHTED EXERCISE PRICE (in dollars per share)	$3.72
$ 2.79 to $4.98 | Minimum	'
OPTIONS OUTSTANDING	'
REMAINING CONTRACTUAL LIFE	'2 months 12 days
$ 2.79 to $4.98 | Maximum	'
OPTIONS OUTSTANDING	'
REMAINING CONTRACTUAL LIFE	'9 years 7 months 6 days
$ 5.34 to $7.13	'
LONG TERM INCENTIVE PLAN & STOCK OPTIONS	'
Exercise price, low end of range (in dollars per share)	$5.34
Exercise price, high end of range (in dollars per share)	$7.13
OPTIONS OUTSTANDING	'
NUMBER OF OPTIONS (in shares)	2,799,400
WEIGHTED EXERCISE PRICE (in dollars per share)	$6.43
OPTIONS EXERCISABLE	'
NUMBER OF OPTIONS (in shares)	2,010,467
WEIGHTED EXERCISE PRICE (in dollars per share)	$6.56
$ 5.34 to $7.13 | Minimum	'
OPTIONS OUTSTANDING	'
REMAINING CONTRACTUAL LIFE	'3 years 9 months 18 days
$ 5.34 to $7.13 | Maximum	'
OPTIONS OUTSTANDING	'
REMAINING CONTRACTUAL LIFE	'9 years 8 months 12 days
$ 8.35 to 11.44	'
LONG TERM INCENTIVE PLAN & STOCK OPTIONS	'
Exercise price, low end of range (in dollars per share)	$8.35
Exercise price, high end of range (in dollars per share)	$11.44
OPTIONS OUTSTANDING	'
NUMBER OF OPTIONS (in shares)	1,534,000
WEIGHTED EXERCISE PRICE (in dollars per share)	$9.15
OPTIONS EXERCISABLE	'
NUMBER OF OPTIONS (in shares)	744,000
WEIGHTED EXERCISE PRICE (in dollars per share)	$8.94
$ 8.35 to 11.44 | Minimum	'
OPTIONS OUTSTANDING	'
REMAINING CONTRACTUAL LIFE	'5 years 9 months 18 days
$ 8.35 to 11.44 | Maximum	'
OPTIONS OUTSTANDING	'
REMAINING CONTRACTUAL LIFE	'9 years 9 months 18 days

LONG_TERM_INCENTIVE_PLAN_STOCK4

LONG TERM INCENTIVE PLAN & STOCK OPTIONS (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Options	'	'	'	'
NUMBER OF UNVESTED OPTIONS	'	'	'	'
Beginning of the period (in shares)	1,714,433	1,579,000	1,529,333	1,609,111
Granted (in shares)	920,500	871,000	839,000	'
Forfeited (in shares)	-58,000	-140,334	-229,998	'
Vested (in shares)	-727,067	-680,999	-688,780	'
End of the period (in shares)	1,714,433	1,579,000	1,529,333	1,609,111
WEIGHTED AVERAGE FAIR MARKET VALUE AT GRANT DATE	'	'	'	'
Granted (in dollars per share)	$3.33	$5.93	$5.06	'
Assumptions used to estimate the fair market value of stock options granted	'	'	'	'
Expected option life	'	'6 years	'6 years	'
Dividend yield (as a percent)	0.00%	0.00%	0.00%	'
Additional disclosures	'	'	'	'
Expiration term	'10 years	'	'	'
Vesting period	'3 years	'	'	'
Options | Minimum	'	'	'	'
Assumptions used to estimate the fair market value of stock options granted	'	'	'	'
Volatility of share price (as a percent)	59.00%	64.00%	63.00%	'
Risk free interest rate (as a percent)	0.10%	0.80%	1.10%	'
Expected option life	'1 year	'	'	'
Options | Maximum	'	'	'	'
Assumptions used to estimate the fair market value of stock options granted	'	'	'	'
Volatility of share price (as a percent)	67.00%	65.00%	64.00%	'
Risk free interest rate (as a percent)	2.00%	1.20%	2.60%	'
Expected option life	'6 years	'	'	'
LTIP	'	'	'	'
Additional disclosures	'	'	'	'
Remaining number of common shares available for equity awards	1,409,165	'	'	'
LTIP | Options	'	'	'	'
Additional disclosures	'	'	'	'
Expiration term	'10 years	'	'	'
Vesting period	'3 years	'	'	'
Compensation expense (in dollars)	$3,877,695	$3,903,795	$3,469,703	'
Unrecorded stock-based compensation expense (in dollars)	$4,117,156	'	'	'
LTIP | Options | Vesting under one year from the grant date	'	'	'	'
NUMBER OF UNVESTED OPTIONS	'	'	'	'
Granted (in shares)	25,000	'	'	'
Additional disclosures	'	'	'	'
Vesting period	'1 year	'	'	'
LTIP | Options | Minimum	'	'	'	'
Additional disclosures	'	'	'	'
Period for amortizing unrecognized compensation cost to expense	'1 month	'	'	'
LTIP | Options | Maximum	'	'	'	'
Additional disclosures	'	'	'	'
Period for amortizing unrecognized compensation cost to expense	'33 months	'	'	'

RISK_MANAGEMENT_Details

RISK MANAGEMENT (Details) (Rockwell Transportation, Inc, USD $)	Dec. 31, 2013
Rockwell Transportation, Inc	'
Risk management	'
Self insurance retention per occurrence	$350,000
Aggregate coverage	784,222
Retention limit in excess of claims paid and accrued	779,000
Estimated additional future claims	293,000
Cash collateral and escrow held by insurance carrier for workers' compensation insurance	$350,000

QUARTERLY_RESULTS_OF_OPERATION2

QUARTERLY RESULTS OF OPERATIONS (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
QUARTERLY RESULTS OF OPERATIONS	'	'	'	'	'	'	'	'	'	'	'
Sales	$13,964,624	$13,094,381	$12,984,164	$12,336,374	$12,999,846	$12,689,339	$12,124,790	$12,028,417	$52,379,543	$49,842,392	$48,966,231
Cost of Sales	11,904,730	11,461,100	11,299,099	11,055,394	11,297,621	11,043,412	10,405,991	10,401,941	45,720,323	43,148,965	43,323,321
Gross Profit	2,059,894	1,633,281	1,685,065	1,280,980	1,702,225	1,645,927	1,718,799	1,626,476	6,659,220	6,693,427	5,642,910
Selling, General and Administrative	3,795,325	3,386,367	3,237,974	3,916,783	3,635,386	3,325,411	2,824,379	2,898,684	14,336,449	12,683,860	9,522,305
Research and Product Development	5,793,579	10,611,219	10,222,721	12,754,518	11,751,256	16,238,450	10,876,396	9,405,547	39,382,037	48,271,649	17,805,362
Operating Income (Loss)	-7,529,010	-12,364,305	-11,775,630	-15,390,321	-13,684,417	-17,917,934	-11,981,976	-10,677,755	-47,059,266	-54,262,082	-21,684,757
Interest and Investment Income, net	69,317	13,546	4,566	10,672	11,034	42,296	77,091	111,097	98,101	241,518	244,049
Interest Expense	872,412	857,505	92,155	75	105	137	456	253	1,822,147	951	1,844
Income (Loss) Before Income Taxes	-8,332,105	-13,208,264	-11,863,219	-15,379,724	-13,673,488	-17,875,775	-11,905,341	-10,566,911	-48,783,312	-54,021,515	-21,442,552
Net Income (Loss)	($8,332,105)	($13,208,264)	($11,863,219)	($15,379,724)	($13,673,488)	($17,875,775)	($11,905,341)	($10,566,911)	($48,783,312)	($54,021,515)	($21,444,557)
Basic And Diluted Earnings (Loss) Per Share (in dollars per share)	($0.21)	($0.34)	($0.38)	($0.72)	($0.66)	($0.86)	($0.58)	($0.54)	($1.48)	($2.65)	($1.21)

SCHEDULE_II_VALUATION_AND_QUAL1

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts	'	'	'
Valuation and Qualifying Accounts	'	'	'
Balance at Beginning of Period	$26,257	$29,473	$23,231
Additions	37,392	9,659	8,527
(Deductions)	-23,474	-12,875	-2,285
Balance at End of Period	37,392	26,257	29,473
Inventory Reserve	'	'	'
Valuation and Qualifying Accounts	'	'	'
Balance at Beginning of Period	27,579	39,803	59,633
Additions	105,647	37,009	18,501
(Deductions)	-98,217	-49,233	-38,332
Balance at End of Period	35,009	27,579	39,803
Deferred Tax Asset Valuation Allowance	'	'	'
Valuation and Qualifying Accounts	'	'	'
Balance at Beginning of Period	38,266,000	19,726,000	11,963,000
Additions	18,006,000	18,540,000	7,763,000
Balance at End of Period	$56,272,000	$38,266,000	$19,726,000